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Scaling up isoniazid preventive therapy in Zimbabwe:  
has operational research influenced policy and practice?
K. C. Takarinda,1,2 R. C. Choto,1 T. Mutasa-Apollo,1 C. Chakanyuka-Musanhu,3 C. Timire,1,2 A. D. Harries2,4
In 2011, the World Health Organization (WHO) re-leased guidelines that recommended strengthening 
intensified tuberculosis (TB) case finding (ICF) and 
scale-up of isoniazid (INH) preventive therapy (IPT) 
among people living with the human immunodefi-
ciency virus (PLHIV) who were enrolled in antiretrovi-
ral therapy (ART) clinics.1 These recommendations 
were based on the knowledge that HIV is the greatest 
risk factor for developing active TB in those with la-
tent infection, with HIV-positive individuals at 20–40 
times higher risk than HIV-negative individuals.1 They 
were also based on evidence showing that despite the 
TB-protective effect of ART, HIV-positive individuals 
still have an increased risk of developing active TB dis-
ease compared to those who are HIV-negative,2 and 
that IPT in combination with ART significantly lowers 
this risk.3–5
As Zimbabwe is one of the 30 countries with the 
highest burden of TB worldwide,6 and a large popula-
tion of PLHIV7 at potential risk of developing active 
TB disease, the WHO ICF/IPT guidelines were adopted 
in 2012, followed by revision of recording and report-
ing tools as well as stakeholder sensitisation meetings 
at various levels of the health system. A feasibility as-
sessment of ICF/IPT implementation was conducted 
over a 1-year period, from December 2012 to Decem-
ber 2013 initially in 10 established ART sites across the 
country, to explore various IPT health delivery models 
the country could use for subsequent national roll-
out. In line with this feasibility assessment, an opera-
tional research (OR) study was conducted in April and 
May 2014 to assess IPT completion rates among PLHIV 
who had started INH over a 2-month period in Quar-
ter (Q) 1, 2013.8 The findings showed IPT completion 
rates of 81%. Among those who did not complete IPT, 
risk factors included 1) IPT pill pick-up visits not syn-
chronised with the 2/3-monthly antiretroviral (ARV) 
pill pick-up visits; 2) a previous history of missed 
clinic visits prior to ART initiation; and 3) being in 
pre-ART care.
Study results and recommendations from the OR 
findings were disseminated in June 2014, and were 
adapted by the National ART Programme (NAP). These 
included 1) agreement with national roll-out of IPT, 
supported by improved supply chain logistics for INH 
to ensure uninterrupted stocks; 2) prioritisation of 
those on ART and synchronised dispensing of INH 
and ARV pills; and 3) cohort-based tracking of patients 
on IPT in health facilities with an electronic patient 
monitoring system (ePMS), to enable assessment of 
completion rates. The monitoring was supplemented 
by periodic supportive visits to all implementing sites 
and regular national review meetings with all 
stakeholders.
To assess what happened after these interventions, 
we conducted a follow-up study among patients en-
rolled in ART clinics within the NAP in Zimbabwe and 
started on IPT between July 2014 and December 2015 
using the same methodology as in the previous study.8 
Specific objectives of this current study were 1) to 
compare, between period A (January 2013–June 2014, 
before the OR recommendations) and period B (July 
2014–December 2015, after the OR recommenda-
tions), the number of PLHIV newly initiated and cu-
mulatively initiated on IPT, the number and distribu-
tion of health facilities offering IPT and the number 
and proportion of PLHIV who completed a full course 
of IPT; and 2) to assess, for period B only (after the OR 
recommendations), factors associated with non-com-
pletion of IPT.
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Setting: Following the operational research study con-
ducted during the isoniazid preventive therapy (IPT) pilot 
phase in Zimbabwe, recommendations for improvement 
were adopted by the national antiretroviral therapy (ART) 
programme.
Objectives: To compare before (January 2013–June 
2014) and after the recommendations (July 2014–De-
cember 2015), the extent of IPT scale-up and IPT com-
pletion rates, and after the recommendations the risk fac-
tors for IPT non-completion, in 530 ART clinics.
Design: Retrospective cohort study.
Results: People living with the human immunodefi-
ciency virus newly initiating IPT increased every quarter 
(Q), from 585 in Q 1, 2013 to 4246 in Q 4, 2015, with 
5648 new IPT initiations in the 18 months before the rec-
ommendations compared to 20 513 in the 18 months 
after the recommendations were made. The number of 
ART clinics initiating IPT increased from 10 (2%) in Q 1, 
2013 to 198 (37%) in Q 4, 2015. Overall IPT completion 
rates were 89% in the post-recommendation period 
compared with 81% in the pilot phase (P  0.001). After 
adjusting for confounders, being lost to follow-up from 
clinic review visits 1 year prior to IPT initiation was associ-
ated with a higher risk of not completing IPT, while hav-
ing synchronised IPT and ART resupplies was associated 
with a lower risk.
Conclusions: Implementation of recommendations from 
the initial operational research study have improved IPT 
scale-up in Zimbabwe.
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STUDY POPULATION, DESIGN AND METHODS
Study design
This was a retrospective cohort study using routine programme 
data.
Study setting
This study was conducted in 530 of 534 high-volume public ART 
clinics in Zimbabwe that were using a fully functional ePMS sys-
tem for tracking individual patients. Four health facilities were 
excluded because they failed to comply with guidelines to submit 
their data backups to national level.
Intensified TB case finding, IPT initiation and enrolment in ART
The process of enrolment into HIV care, routine ICF and record-
ing and reporting in Zimbabwe have been described in the previ-
ous study.8 While all patients enrolled in HIV care were eligible for 
IPT on exclusion of TB symptoms using the WHO’s four symptom 
based TB screening tool, there have been changes over time. First, 
the NAP has gradually modified eligibility for starting ART: in 
2013 the CD4 cell count threshold was 350 cells/ml; this moved 
to 500 cells/ml in January 2014, and remained as such during 
the period of the study. From 2016, Zimbabwe moved to the ‘HIV 
Treat All’ approach; however, this occurred after the current study 
was completed. Second, since the previous OR study and the rec-
ommendations that were made, supplies of the 6-month daily 
oral dose of INH (5 mg/kg body weight for adults or 10 mg/kg 
body weight for children) plus daily low-dose pyridoxine (25 mg/
day) have been synchronised with the ARV resupplies until com-
pletion of prophylactic treatment to prevent unnecessary visits to 
the health facility. During clinic visits, patients are assessed for ad-
herence through self-reports and pill counts, and they also un-
dergo screening for TB. Those found to have developed active TB 
disease discontinue IPT and are treated for TB according to na-
tional TB guidelines.9 After completion of a 6-month course of 
IPT, patients become eligible again for another repeat course of 
IPT after 36 months, when TB risk again increases.
Patient sample
The study included all confirmed PLHIV enrolled in HIV treat-
ment and care services, commenced on IPT between 1 January 
2013 and 31 December 2015 and entered in the ePMS across 530 
ART clinics nationwide.
Data variables, data source and data collection
The variables of interest were similar to those in the previous 
study.8 This time, however, data were obtained from the ePMS, 
and included information such as start dates for IPT and quanti-
ties of IPT pills dispensed throughout the 6-month course of pro-
phylaxis. As data on pharmacy stock status by health facility are 
not entered in the ePMS, unlike the previous study we could not 
establish site-specific INH stock status throughout the period un-
der study.
Statistical analysis
Data from all individual ePMS back-ups, which are in MySQL da-
tabase format (Oracle International Corporation, Redwood City, 
CA, USA) were imported into Stata v 15.1 (Stata Corporation, Col-
lege Station, TX, USA) prior to data cleaning and statistical analy-
sis. Frequencies and proportions were generated for categorical 
variables. Variables that produced a P value of 0.25 for χ2 associ-
ations with IPT non-completion were included in the multivari-
ate log-binomial regression model for determining risk factors as-
sociated with IPT non-completion. Results were presented as 
relative risks (RRs) with 95% confidence intervals, and level of sig-
nificance was set at 5% (P  0.05).
Ethics
Ethics approval was granted locally by the Medical Research 
Council of Zimbabwe and internationally by the Ethics Advisory 
Group of the International Union Against Tuberculosis and Lung 
Disease, Paris, France. As only secondary data were used, in-
formed patient consent was not required.
RESULTS
Scale-up in uptake of IPT and comparisons of IPT 
completion rates
The number of PLHIV in ART clinics newly initiated on IPT was 
lowest in Q 1, 2013, at 585, but increased every quarter to a high 
of 4246 new initiations by Q 4, 2015 (Figure 1). Overall, during 
FIGURE 1 Number of PLHIV already enrolled in public ART clinics and newly initiated each quarter on 
IPT in Zimbabwe, January 2013–December 2015. IPT = isoniazid preventive therapy; Q = quarter; PLHIV 
= people living with the human immunodeficiency virus; ART = antiretroviral therapy.
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period A there were 5648 new IPT initiations, compared to 20 513 
during period B. The numbers of PLHIV cumulatively started on 
IPT reached 5648 during the 18 months of period A, and in-
creased to 26 161, a five-fold increase, during the 18 months of 
period B (Figure 2). In addition to the numbers of PLHIV initiated 
on IPT, there were also increases in the number of sites offering 
IPT over time. Of the 530 established ART clinics, the number of-
fering IPT increased from 10 to 92 (2–17%) during period A and 
from 92 to 198 (17–37%) during period B (Figure 3). Compared to 
Q 1, 2013 in period A, when the IPT completion rate was 81%, 
the IPT completion rates for period B increased significantly to 
89% overall (P  0.001), with a peak of 97% in Q 1, 2015 and a 
trough of 71% in Q 4, 2015 (Figure 4). 
Demographic and clinical characteristics of PLHIV starting 
IPT between July 2014 and December 2015
The demographic and clinical characteristics of PLHIV who 
started on IPT during period B (July 2014–December 2015) are 
shown in Tables 1 and 2, respectively. The median age of those 
started on IPT was 38 years (interquartile range [IQR] 30–46); the 
majority were females (66%), of whom 236 (2%) were pregnant. 
Half of the patients were accessing care at secondary-level hospi-
tals and 44% were at primary care facilities. A documented past 
FIGURE 2 Cumulative number of PLHIV ever started on IPT at public ART clinics in Zimbabwe, January 
2013–December 2015. IPT = isoniazid preventive therapy; Q = quarter; PLHIV = people living with the 
human immunodeficiency virus; ART = antiretroviral therapy.
FIGURE 3 Cumulative number of selected ART clinics with access to the ePMS offering IPT in Zimba-
bwe, January 2013–December 2015. Q = quarter; ART = antiretroviral therapy; ePMS = electronic Patient 
Monitoring System; IPT = isoniazid preventive therapy.
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TABLE 1 Demographic characteristics of PLHIV commenced on IPT 
in ART clinics with the electronic Patient Monitoring System in 
Zimbabwe, 1 July 2014–31 December 2015
Variable n (%)
Total 20 510 (100)
Age group, years
 25 2 587 (12.6)
 25–34 5 184 (25.3)
 35–44 6 744 (32.9)
 45 5 995 (29.2)
 Data missing —
Sex
 Female 13 580 (66.2)
 Male 6 930 (33.8)
 Data missing —
Pregnancy status*
 No 12 441 (93.2)
 Yes 236 (1.8)
 Data missing 669 (5.0)
Marital status*
 Married 12 165 (60.7)
 Single 2 953 (14.7)
 Widowed 2 979 (14.9)
 Divorced 1 318 (6.6)
 Data missing 620 (3.1)
Education level†
 Primary or less 3 499 (17.2)
 Secondary or higher 7 087 (34.9)
 Data missing 9 715 (47.9)
Type of health facility where patient is enrolled for IPT
 Primary health care 8 924 (43.5)
 District/mission hospital 10 159 (49.5)
 Provincial hospital 12 (0.06)
 Central hospital 1 415 (6.9)
* Restricted to those aged >10 years.
† Excluding those aged 6 years.
PLHIV = people living with HIV; HIV = human immunodeficiency virus; IPT = isonia-
zid preventive therapy; ART = antiretroviral treatment.
TABLE 2 Clinical characteristics of PLHIV commenced on IPT in 
ART clinics with the electronic Patient Monitoring System in 
Zimbabwe, July 2014–December 2015
Variable n (%)
Total 20 510 (100)
WHO stage at enrolment
 IV 237 (1.2)
 III 4 009 (19.6)
 II 2 472 (12.1)
 I 1 948 (9.5)
 Data missing 11 844 (57.8)
Baseline CD4 count, cells/ml
 200 3 030 (14.8)
 201–350 2 017 (9.8)
 351–500 771 (3.8)
 >500 598 (2.9)
 Data missing 14 094 (68.7)
Documented past TB treatment
 No 19 626 (95.7)
 Yes 884 (4.3)
Current ART status
 Pre-ART 55 (0.3)
 On ART 20 455 (99.7)
Patient follow-up visit status in the past year
 On time* 13 543 (66.0)
 Delay in scheduled visits of 7–90 days 6 967 (34.0)
Quantity of IPT dispensed at initial visit, months
 1 2 277 (11.1)
 2 18 233 (88.9)
* Within 7 days of scheduled appointment.
PLHIV = people living with HIV; HIV = human immunodeficiency virus; IPT = isonia-
zid preventive therapy; ART = antiretroviral therapy; WHO = World Health Organiza-
tion; TB = tuberculosis.
FIGURE 4 Number and proportion of PLHIV enrolled in ART clinics and started on IPT who completed 
IPT, January 2013–December 2015.* * There were no data on IPT completion rates for Q2 2013–Q2 
2014. IPT = isoniazid preventive therapy; Q = quarter; PLHIV = people living with the human immunode-
ficiency virus; ART = antiretroviral therapy. 
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history of TB was recorded for 884 (4%) participants, and 1% 
were in pre-ART care. A history of loss to follow-up from ART in 
the year prior to IPT initiation was recorded for 6967 (34%) pa-
tients. A high proportion (89%) of PLHIV on IPT initially received 
an IPT supply of 2 months.
Risk factors associated with non-completion of IPT
Risk factors for non-completion of IPT are shown in Table 3. Simi-
lar to the previous study, having a history of loss to follow-up 
from clinic review visits in the year prior to IPT initiation was as-
sociated with a higher risk of not completing the 6-month course 
of IPT, while synchronising the IPT and ARV resupplies was associ-
ated with a lower risk of not completing the 6-month IPT course.
DISCUSSION
This study shows notable improvements in Zimbabwe’s national 
IPT programme following the adoption of recommendations by 
the Zimbabwe HIV Care and Treatment Programme that arose 
from the OR study conducted during the feasibility phase of IPT in 
the 10 pilot sites.8 There were significant increases in PLHIV started 
on IPT, and in the number of health facilities offering IPT over 
time. Notably, in line with recommendations, the HIV Care and 
Treatment programme was able to conduct routine quarterly co-
hort-based assessments of IPT completion rates in health facilities 
based on the ePMS system. Progress is underway in these health 
facilities to have a dashboard on the ePMS system that readily re-
ports IPT completion rates to inform immediate follow-up or trac-
ing of those patients with poor completion rates or who may be 
lost to follow-up. For those health facilities that do not have access 
to the ePMS (which were not included in the study), there is 
monthly reporting of aggregate IPT indicators, including number 
of PLHIV screened for TB, number eligible for IPT, number started 
on IPT and number who completed their 6-month IPT course.
In line with recommendations, there was an increase in the 
proportion of patients who had the correct quantity of IPT dis-
pensed and clinic review visits synchronised with ART resupplies, 
TABLE 3 Risk factors associated with non-completion of IPT among PLHIV enrolled in ART clinics with the electronic Patient Monitoring 
System, Zimbabwe, July 2014–December 2015
Variable
Total
N
IPT non-completers
n (%)
Unadjusted RR
(95%CI)
Adjusted RR
(95%CI)
Total 20 510 2 290 (11.2)
Age group, years
 25 2 587 409 (15.8) Reference Reference
 25–34 5 184 524 (10.1) 0.64 (0.57–0.72) 1.07 (0.97–1.20)
 35–44 6 744 710 (10.5) 0.67 (0.59–0.75) 1.02 (0.92–1.13)
 45 5 995 647 (10.8) 0.68 (0.61–0.77) 1.02 (0.92–1.13)
Sex
 Female 13 580 1 467 (10.8) Reference Reference
 Male 6 930 823 (11.9) 1.10 (1.01–1.19) 0.98 (0.06–15.26)
Pregnancy status
 No 13 344 1 438 (10.8) Reference Reference
 Yes 236 29 (12.3) 1.01 (1.00–1.02) 1.01 (0.74–1.37)
Type of health facility where patient is enrolled for IPT
 Primary health care 8 924 736 (8.25) Reference Reference
 First referral level 10 159 1 272 (12.5) 1.52 (1.39–1.65) 1.06 (0.99–1.14)
 Second/third referral level 1 427 282 (19.8) 2.40 (2.11–2.72) 0.94 (0.84–1.05)
WHO stage at enrolment
 IV 237 35 (14.77) Reference Reference
 III 4 009 497 (12.4) 0.84 (0.61–1.15) 1.02 (0.78–1.34)
 II 2 472 319 (12.9) 0.87 (0.63–1.21) 1.17 (0.89–1.54)
 I 1 948 181 (9.3) 0.63 (0.45–0.88) 0.94 (0.71–1.26)
 Not recorded 11 844 1 257 (10.6) 0.72 (0.53–0.98) 1.07 (0.82–1.40)
Documented past TB treatment
 No 19 626 2 172 (11.1) Reference Reference
 Yes 884 118 (13.4) 1.21 (1.01–1.43) 1.07 (0.93–1.23)
Current ART status
 Not eligible based on ART starting criteria 55 4 (7.3) Reference Reference
 On ART 20 455 2 286 (11.2) 1.54 (0.60–3.95) 2.31 (0.97–5.52)
Patient follow-up visit status in the past year
 On time* 13 543 1 356 (9.5) Reference Reference
 Delay in scheduled visits of 7–90 days 6 967 1 008 (14.5) 1.53 (1.41–1.65) 1.20 (1.12–1.28)
Quantity of IPT dispensed at initial visit, months
 1 2 782 1 356 (48.7) Reference Reference
 2 17 728 934 (5.3) 0.11 (0.10–0.12) 0.11 (0.10–0.12)
* Within 7 days of scheduled appointment.
IPT = isoniazid preventive therapy; PLHIV = people living with HIV; HIV = human immunodeficiency virus; ART = antiretroviral therapy; RR = relative risk; CI = confidence inter-
val; WHO = World Health Organization.
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from 58% in the pilot study to 89% in the current study.8 This 
correlated with an improvement in overall IPT completion rates 
from 81% to 89% in the current study compared to the previous 
study.8 Although a higher proportion of PLHIV had a history of 
loss to follow-up from ART in the current compared to the previ-
ous study,8 this did not in general lower IPT completion rates; this 
may be attributed to targeted enhanced adherence counselling, 
which has been shown to improve ART adherence in those who 
are not virally suppressed.10 There was also a decline in the pro-
portion of PLHIV started on IPT while in pre-ART care between 
the previous and current study, from 5% to 1%, although this 
probably coincided with a shift in the ART eligibility criteria from 
350 cells/ml to 500 cells/ml: these policy changes may also 
have led indirectly to improved IPT completion rates compared 
with the previous OR study.11–13
Of concern were the declining IPT completion rates, which 
were at 84% in Q 3, 2015 and 71% in Q 4, 2015, as shown in Fig-
ure 4. We do not know the precise reasons for this, which might 
be due to data quality issues or to discontinuation of IPT follow-
ing anecdotal reports of IPT toxicity by health workers. While ad-
verse drug reactions are routinely reported to the national level, 
they may not be routinely reported through the Adverse Drug Re-
action (ADR) reporting system as has been recommended. These 
are all areas that require further OR.
The strengths of this study are two-fold. First, the same meth-
odology was employed in this follow-up study as in the previous 
study, thus enabling an assessment of the impact of changes in 
practice following the initial study. Second, the current study had 
a large sample size with wide geographic coverage and representa-
tion of the different tiers of the public health system in Zimba-
bwe, making the study results generalisable to the entire country. 
Study limitations included missing data for some variables and no 
data on IPT stock levels, as they required abstraction from pa-
per-based records at ART clinics under assessment. Furthermore, 
no qualitative assessment was done concurrently to provide infor-
mation on reasons for not completing IPT.
In conclusion, this study demonstrates that OR can play a piv-
otal role in evidence-based decision making. Recommendations 
were made following the initial OR study on IPT implementation 
which could then be assessed in terms of impact on policy, prac-
tice and programmatic scale-up of IPT. This is an approach that 
should be taken up by health programmes as a means of identify-
ing programmatic challenges through research and eventually 
putting in place interventions that can enhance the quality or 
coverage of health services.
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Contexte  :  A la suite d’une recherche opérationnelle réalisée pendant 
la phase pilote du traitement préventif par isoniazide (TPI) au 
Zimbabwe, des recommandations visant à une expansion ont été 
adoptées par le programme national de traitement antirétroviral 
(TAR).
Objectifs  :  Dans 530 centres de TAR, comparer avant (janvier 2013 à juin 
2014) et après les recommandations (juillet 2014 à décembre 2015), le 
degré d’expansion du TPI et ses taux d’achèvement, et après les 
recommandations, examiner les facteurs de risque de non achèvement.
Schéma  :  Cohorte rétrospective.
Résultats  :  Le nombre des personnes vivant avec le virus de 
l’immunodéficience humaine démarrant le TPI ont augmenté chaque 
trimestre de 585 pendant le premier trimestre de 2013 à 4246 
pendant le quatrième trimestre de 2015, avec 5648 nouvelles mises 
en route du TPI dans les 18 mois avant les recommandations et 20 
513 dans la période de 18 mois après les recommandations. Le 
nombre de centres de TAR mettant en route le TPI a augmenté de 10 
(2%) au premier trimestre 2013 à 198 (37%) au quatrième trimestre 
2015. Les taux d’ensemble d’achèvement du TPI ont été de 89% 
dans la période suivant les recommandations comparés à 81% 
pendant la phase pilote (P  0,001). Après ajustement sur les facteurs 
de confusion, le fait d’être perdus de vue des consultations de suivi 
au centre 1 an avant la mise en route du TPI a été associé à un risque 
plus élevé de non achèvement du TPI, tandis que la synchronisation 
du renouvellement des fournitures du TPI et du TAR a été associée à 
un risque plus faible.
Conclusions  :  Les recommandations émanant de la recherche 
opérationnelle initiale ont amélioré l’expansion du TPI au Zimbabwe.
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Marco de referencia: El programa nacional de tratamiento 
antirretrovírico (TAR), tras una investigación operativa realizada 
durante la fase preliminar de aplicación del tratamiento preventivo 
con isoniazida (TPI) en Zimbabwe, adoptó las medidas de 
mejoramiento que se recomendaban.
Objetivos: Comparar en 530 consultorios de suministro del TAR la 
magnitud de la ampliación de escala del TPI y las tasas de compleción 
del mismo, antes (de enero del 2013 a junio del 2014) y después (de 
julio del 2014 a diciembre del 2015) de la puesta en práctica de las 
recomendaciones, y después de su adopción, examinar los factores 
de riesgo de no completar el TPI.
Método: Fue este un estudio de cohortes retrospectivo.
Resultados: El número de personas infectadas por el virus de la 
inmunodeficiencia humana que iniciaban el TPI aumentó en cada 
trimestre, de 585 en el primer trimestre del 2013 a 4246 en el 
cuarto trimestre del 2015; se contabilizaron 5648 nuevos inicios del 
TPI en los 18 meses que precedieron la aplicación de las 
recomendaciones y 20 513 casos en los 18 meses que siguieron a la 
puesta en práctica de las mismas. El número de consultorios de TAR 
que iniciaban el TPI aumentó de 10 (2%) en el primer trimestre del 
2013 a 198 (37%) en el cuarto trimestre del 2015. La tasa de 
compleción global del TPI fue 89% en el período posterior a las 
recomendaciones, comparada con 81% en la fase preliminar (P  
0,001). Tras corregir con respecto a las variables de confusión, la 
pérdida durante el seguimiento en las citas de control en el 
consultorio durante el año anterior a la iniciación del TPI se asoció 
con un mayor riesgo de no completar el TPI; al contrario, la 
sincronización del suministro del TPI y el TAR se asoció con una 
disminución del riesgo.
Conclusión: La aplicación de las medidas recomendadas durante la 
investigación operativa inicial ha mejorado la ampliación de escala 
del suministro del TPI en Zimbabwe.
